# Henan Celnovte Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/henan-celnovte-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Zhengzhou, China
- Website: www.celnovte-bio.com
- Latest round: Series A (Dec 25, 2018)
- Investors on record: 1

## About

Established in 2010 and based in Zhengzhou, China, Henan Celnovte Biotechnology Co., Ltd. is a medical device company that focuses on the development and production of tumor pathology diagnostic instruments and reagents. In 2019, it built a 5,000-square-meter tumor pathology diagnostic instrument production base and launched an automatic immunohistochemistry staining machine and in situ hybridization instrument. It has obtained 443 Class I registration certificates for medical devices and 56 CE-IVD certifications as of 2022. It has partnerships with Henan Cancer Hospital, Henan Provincial People's Hospital, the First Affiliated Hospital of Zhengzhou University, the First Affiliated Hospital of Xinxiang Medical College, West China Hospital of Sichuan University, Shanghai Ruijin Hospital, and Xiangya Hospital of Central South University. It is headquartered in Zhengzhou and has branches in the US and Shenzhen.

The company specializes in the development, production and sales services of tumor pathology, hematology-tumor, cytogenetic, tuberculosis culture and drug-sensitive diagnostic instruments and reagents. Their self-developed products include molecular pathology diagnostic product R&D and production platform, immunohistochemistry antibody R&D and production platform, flow fluorescence antibody R&D and production platform, pathology staining solution R&D and production platform, Mycobacterium tuberculosis culture medium production platform, chromosome culture medium production platform. Their products are used in the field of immunohistochemistry, molecular pathology, and tissue staining pathology.

## Funding rounds

- Series A, Dec 25, 2018 — Puhua Capital

## Investors

- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A